Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2014;71(4):151-7.
doi: 10.1080/09674845.2014.11669980.

Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes

Affiliations
Controlled Clinical Trial

Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes

J Farhan et al. Br J Biomed Sci. 2014.

Abstract

Vitiligo is a pigmentation disorder of unknown aetiology, but it has been reported in association with other autoimmune diseases including type 1 diabetes mellitus (T1D). Vitiligo and T1D share a common theory of autoimmunity, but still an inflammatory link between them remains to be investigated. This study investigates the status and contribution of the inflammatory markers tumour necrosis factor-α (TNFα), interleukin (IL)-6 and IL-1 in patients with vitiligo, T1D and vitiligo-associated T1D (Vt-T1D). The data showed that sera from Vt-T1D patients (n = 21) had higher levels of TNFα, IL-6 and IL-1β compared with vitiligo patients (n = 39), T1D patients (n = 37) or controls (n = 42). Interestingly, serum levels of IL-6 were found to be significantly higher in Vt-T1D patients compared with the levels of TNFα and IL-1β. These data also showed that IL-6 was high in Vt patients as compared to the levels of TNFa and L-1β, whereas in T1D patients, IL-6 and TNFα were almost the same but were higher than IL-1β. In conclusion, this is the first study to show an inflammatory link between vitiligo and T1D. The data conclude that IL-6 plays an important role in the pathogenesis of Vt-T1D patients and is likely to gain favour as a therapeutic target in these patients.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources